The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Regulatory News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: -106.00 (-0.87%)
Spread: 2.00 (0.017%)
Open: 12,092.00
High: 12,178.00
Low: 12,010.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Replacement - Form 8 (OPD) (Pfizer)

21 May 2014 11:49

RNS Number : 6933H
Pfizer Inc
21 May 2014
 

FORM 8 (OPD)

 

PUBLIC OPENING POSITION DISCLOSURE BY A PARTY TO AN OFFER

Rules 8.1 and 8.2 of the Takeover Code (the "Code")

 

AMENDMENT - CHANGES TO SECTION 3.2

 

1. KEY INFORMATION

 

(a) Identity of the party to the offer making the disclosure:

Pfizer Inc. ("Pfizer")

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

N/A

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

AstraZeneca PLC

(d) Is the party to the offer making the disclosure the offeror or the offeree?

Offeror

(e) Date position held:

9 May 2014

(f) Has the party previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer?

Yes, Pfizer Inc.

 

2. POSITIONS OF THE PARTY TO THE OFFER MAKING THE DISCLOSURE

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates

 

Class of relevant security:

 

Ordinary Shares

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

Nil

Nil

(2) Derivatives (other than options):

Nil

Nil

(3) Options and agreements to purchase/sell:

Nil

Nil

 

TOTAL:

Nil

Nil

 

 

(b) Rights to subscribe for new securities

 

Class of relevant security in relation to which subscription right exists:

None

Details, including nature of the rights concerned and relevant percentages:

N/A

 

 

(c) Irrevocable commitments and letters of intent

 

Details of any irrevocable commitments or letters of intent procured by the party to the offer making the disclosure or any person acting in concert with it (see Note 3 on Rule 2.11 of the Code):

 

None.

 

 

3. POSITIONS OF PERSONS ACTING IN CONCERT WITH THE PARTY TO THE OFFER MAKING THE DISCLOSURE

 

Details of any interests, short positions and rights to subscribe of any person acting in concert with the party to the offer making the disclosure:

 

See below

 

 

3.1 Pfizer Directors

 

Name of Director

Number of Ordinary Shares[1] held

Percentage of total issued ordinary shares (excluding treasury shares)

Stephen W. Sanger

161

0.00%

 

 

3.2 Advisers to Pfizer [2]

 

J.P. Morgan (J.P. Morgan Securities plc and J.P. Morgan Trust Company of Delaware)

 

Class of relevant security:

 

Ordinary Shares

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

52,606

0.00%

Nil

(2) Derivatives (other than options):

Nil

Nil

(3) Options and agreements to purchase/sell:

Nil

Nil

 

TOTAL:

52,606

0.00%

Nil

 

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the party to the offer making the disclosure or any person acting in concert with it:

 

None.

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the party to the offer making the disclosure, or any person acting in concert with it, and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

 

None.

 

 

(c) Attachments

 

Are any Supplemental Forms attached?

 

Supplemental Form 8 (Open Positions)

No

Supplemental Form 8 (SBL)

No

 

 

Date of disclosure:

12 May 2014

Contact name:

Chris Dickinson

Geoff Iles

Telephone number:

+44 (0) 207 134 7302

+44 (0) 207 995 1930

 


[1] Comprises AstraZeneca ordinary shares held by Stephen W. Sanger 's close relatives, whether directly or in trust (to his knowledge after inquiry).

[2] The information in this section was provided to Pfizer by the relevant adviser

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FEEBFLFLZEFZBBL
Date   Source Headline
18th Aug 20207:00 amRNSImfinzi US Priority Review; four-week, fixed dose
4th Aug 20207:00 amRNSAstraZeneca prices a $3bn bond issue
3rd Aug 20203:00 pmRNSTotal Voting Rights
30th Jul 20207:25 amRNSTagrisso US BTD for EGFRm adjuvant lung cancer
30th Jul 20207:18 amRNSAZN: H1 2020 results
29th Jul 20207:00 amRNSBoard Committee Changes
28th Jul 20207:00 amRNSFarxiga DAPA-CKD trial met all endpoints
27th Jul 20207:10 amRNSCalquence receives positive CHMP opinion for CLL
27th Jul 20207:05 amRNSImfinzi recommended for EU approval in SCLC
27th Jul 20207:00 amRNSAstraZeneca enters collaboration in oncology
24th Jul 20207:00 amRNSBreztri Aerosphere approved in the US for COPD
22nd Jul 20203:00 pmRNSHolding(s) in Company
22nd Jul 20203:00 pmRNSHolding(s) in Company
21st Jul 20203:00 pmRNSHolding(s) in Company
21st Jul 20203:00 pmRNSHolding(s) in Company
20th Jul 20202:41 pmRNSCOVID-19 vaccine Phase I/II showed immune response
16th Jul 20207:00 amRNSDirector Declaration
9th Jul 20207:00 amRNSBrilinta granted US FDA Priority Review for stroke
8th Jul 20207:00 amRNSLynparza approved in the EU for pancreatic cancer
1st Jul 20203:00 pmRNSTotal Voting Rights
30th Jun 20203:00 pmRNSDirector/PDMR Shareholding
30th Jun 20207:00 amRNSSelumetinib granted Japan orphan drug designation
17th Jun 20203:03 pmRNSHolding(s) in Company
17th Jun 20203:00 pmRNSHolding(s) in Company
15th Jun 20207:00 amRNSAgreement to Supply Europe with COVID-19 Vaccine
11th Jun 20207:00 amRNSEMTN Programme Routine Technical Update
1st Jun 20203:00 pmRNSBlock listing Interim Review
1st Jun 20203:00 pmRNSTotal Voting Rights
1st Jun 20207:00 amRNSLynparza EU CHMP opinion in pancreatic cancer
1st Jun 20207:00 amRNSBrilinta obtains additional US approval
29th May 20204:41 pmRNSSecond Price Monitoring Extn
29th May 20204:35 pmRNSPrice Monitoring Extension
29th May 20201:00 pmRNSImfinzi sustained overall survival in CASPIAN
29th May 20201:00 pmRNSEnhertu DESTINY-Gastric01 results from ASCO 2020
29th May 20207:00 amRNSTagrisso unprecedented adjuvant lung cancer data
26th May 202010:30 amRNSDirector/PDMR Shareholding
22nd May 20207:00 amRNSEnhertu US orphan designation in gastric cancer
21st May 20207:00 amRNSAstraZeneca advances response to COVID-19 outbreak
20th May 20207:00 amRNSLynparza approved in the US for prostate cancer
18th May 20207:00 amRNSEnhertu US Breakthrough status for lung cancer
18th May 20207:00 amRNSBevespi Aerosphere approved in China for COPD
11th May 20207:00 amRNSBrazikumab rights recovered by AstraZeneca
11th May 20207:00 amRNSEnhertu designated gastric cancer BTD
11th May 20207:00 amRNSLynparza gets broader US ovarian cancer approval
6th May 20207:00 amRNSFarxiga approved by FDA for heart failure (HFrEF)
1st May 20203:00 pmRNSTotal Voting Rights
29th Apr 20204:00 pmRNSResult of AGM
29th Apr 20207:00 amRNSAZN: first-quarter 2020 results
24th Apr 20207:00 amRNSLynparza shows overall survival in prostate cancer
17th Apr 202011:00 amRNSChanges to arrangements for AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.